Cebranopadol - Grunenthal GmbH

Drug Profile

Cebranopadol - Grunenthal GmbH

Alternative Names: GRT-6005

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Grunenthal
  • Developer Allergan; Grunenthal
  • Class Cyclohexylamines; Indoles; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nociceptin receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Back pain; Diabetic neuropathies; Musculoskeletal pain
  • No development reported Postoperative pain

Most Recent Events

  • 01 Mar 2018 Cebranopadol is no more licensed to Depomed in USA and Canada
  • 30 Sep 2016 Efficacy and adverse events data from a phase III trial in Cancer pain released by Grunenthal
  • 16 Sep 2016 Pharmacodynamics data from a preclinical study in Pain presented at the 16th World Congress on Pain (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top